臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

	English \| 正體中文 \| 简体中文 \| 總筆數 :0
	造訪人次 : 52846677 線上人數 : 653 教育部委託研究計畫計畫執行:國立臺灣大學圖書館

搜尋範圍

進階搜尋

登入

管理

臺灣學術機構典藏系統 (Taiwan Academic Institutional Repository, TAIR)

關於TAIR
	計畫說明

瀏覽
	典藏機構
	作者
	題名
	日期
	統計圖表
	機構即時統計
	學術趨勢

消息
	2019臺灣學術機構典藏研討會
	機構典藏系統RC7版本已發佈

著作權
	出版社及期刊政策查詢
	TAIR著作權會議記錄

相關連結
	機構典藏計畫網站
	ROAR
	OpenDOAR
	SHERPA
	OAIster
	JAIRO
	Ira
	DSPACE
	RWWR
	臺大學術典藏NTU Scholars

"shih j y"的相關文件

回到依作者瀏覽
依題名排序	依日期排序

顯示項目 406-415 / 1137 (共114頁)
<< < 36 37 38 39 40 41 42 43 44 45 > >>
每頁顯示[10|25|50]項目

機構	日期	題名	作者
臺大學術典藏	2021-03-11T08:34:15Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	SHENG-KAI LIANG; LI-TA KENG; CHIA-HAO CHANG; Wen Y.-F.; MENG-RUI LEE; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T08:34:15Z	Effect of β-Blocker in Treatment-Naive Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs	Chang C.-H.;Lee C.-H.;Jen-Chang Ko;Chang L.-Y.;Lee M.-C.;Zhang J.-F.;Wang J.-Y.;Shih J.-Y.;Yu C.-J.; CHIA-HAO CHANG; Lee C.-H.; JEN-CHANG KO; LIH-YU CHANG; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T08:29:35Z	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma	Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T08:29:34Z	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study	Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T08:29:32Z	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y.
臺大學術典藏	2021-03-11T08:29:30Z	Effect of β-Blocker in Treatment-Na?ve Patients With Advanced Lung Adenocarcinoma Receiving First-Generation EGFR-TKIs	Chang C.-H.; Lee C.-H.; JEN-CHANG KO; Chang L.-Y.; Lee M.-C.; Zhang J.-F.; Wang J.-Y.; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T08:29:29Z	Treatment Options of First-Line Tyrosine Kinase Inhibitors and Subsequent Systemic Chemotherapy Agents for Advanced EGFR Mutant Lung Adenocarcinoma Patients: Implications From Taiwan Cancer Registry Cohort	Liang S.-K.; Keng L.-T.; Chang C.-H.; Wen Y.-F.; Lee M.-R.; Yang C.-Y.; Wang J.-Y.; JEN-CHANG KO; Shih J.-Y.; Yu C.-J.
臺大學術典藏	2021-03-11T07:58:31Z	Real-world experience of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma	Liang S.-K.; Hsieh M.-S.; Lee M.-R.; Keng L.-T.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T07:58:28Z	Prognostic factors of afatinib as a first-line therapy for advanced EGFR mutation-positive lung adenocarcinoma: A real-world, large cohort study	Liang S.-K.; Lee M.-R.; Liao W.-Y.; Ho C.-C.; JEN-CHANG KO; Shih J.-Y.
臺大學術典藏	2021-03-11T07:58:27Z	Afatinib is effective in the treatment of lung adenocarcinoma with uncommon EGFR p.L747P and p.L747S mutations	Liang S.-K.; JEN-CHANG KO; Yang J.C.-H.; Shih J.-Y.

顯示項目 406-415 / 1137 (共114頁)
<< < 36 37 38 39 40 41 42 43 44 45 > >>
每頁顯示[10|25|50]項目